National Institute of General Medical Sciences; Notice of Closed Meeting, 19637 [2014-07863]

Download as PDF Federal Register / Vol. 79, No. 68 / Wednesday, April 9, 2014 / Notices TKELLEY on DSK3SPTVN1PROD with NOTICES research to further develop, evaluate or commercialize Ex-vivo Production of Regulatory B-Cells (Breg). For collaboration opportunities, please contact Alan Hubbs, Ph.D. at hubbsa@ mail.nih.gov. SCGB3A2 for Treatment of Cancer Description of Technology: A novel method of treating lung cancer using uteroglobin-related protein 1 (UGRP1), also known as secretoglobin family 3A member 2 (SCGB3A2) is disclosed. SCGB3A2 is a member of the uteroglobin/Clara cell secretory protein or Secretoglobin gene superfamily of secretory proteins that is predominantly expressed in the epithelial cells of the trachea, bronchus, and bronchioles, and is known for its anti-inflammatory activity. The inventors have previously discovered the growth factor and antifibrotic activities of SCGB3A2 and proposed the use of SCGB3A2 as a therapeutic to treat neonatal respiratory distress and as an agent to promote lung development, and to inhibit or reduce pulmonary fibrosis caused by an anticancer agent. Recently, the inventors have made a surprising discovery that the secretory protein SCGB3A2 also has anti-cancer activity, in addition to its known growth factor, antiinflammatory, and anti-fibrotic activities. The inventors have used SCGB3A2-induced inhibition of metastasis in the iv- and sc-injected LLC cells lung metastasis model, Scgb3a2null mice injected with LLC cells with and without SCGB3A2, and Scgb3a2lung transgenic mice subjected to tobacco carcinogen induced mouse carcinogenesis bioassay to confirm their discovery that SCGB3A2 has anti-cancer activity. Potential Commercial Applications: Therapeutics for treating cancers. Competitive Advantages: • This technology provides, for the first time, a new mode of treating lung cancer using SCGB3A2. • Because SCGB3A2 is predominantly expressed in lung airways, low toxicity is anticipated by the use of SCGB3A2 as a therapeutic. • Unique mode of action (affects both metastasis and growth (proliferation) of cancer cells) makes SCGB3A2 more effective as a therapeutic. Development Stage: • Early-stage. • In vitro data available. • In vivo data available (animal). Inventors: Kimura Shioko, Cai Yan, and Murata Miyuki (NCI). Publication: Cai Y, et al. Preclinical evaluation of human secretoglobin 3A2 in mouse models of lung development and fibrosis. Am J Physiol Lung Cell VerDate Mar<15>2010 17:54 Apr 08, 2014 Jkt 232001 Mol Physiol. 2014 Jan 1;306(1):L10–22. [PMID 24213919]. Intellectual Property: HHS Reference No. E–286–2006/3—US Provisional Patent Application No. 61/862,429 filed 05 Aug 2013. Related Technologies: HHS Reference Nos. E–286–2006/0, 1, 2– • US Patent No. 8,133,859 issued 13 Mar 2012. • US Patent No. 8,501,688 issued 06 Aug 2013. • US Patent Application No. 13/ 959,628 filed 05 Aug 2013. Licensing Contact: Suryanarayana (Sury) Vepa; 301–435–5020; vepas@ mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute, Laboratory of Metabolism, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize SCGB3A2 as an anticancer reagent, which mainly works through the JNK pathway. For collaboration opportunities, please contact John D. Hewes, Ph.D. at hewesj@ mail.nih.gov. Dated: April 3, 2014. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2014–07871 Filed 4–8–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of General Medical Sciences; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review of Grant Applications. Date: May 2, 2014. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 19637 Place: National Institutes of Health, Natcher Building, 45 Center Drive, Room 3An.18B, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Margaret J. Weidman, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3An.18B, Bethesda, MD 20892, 301–594–2773, weidmanma@nigms.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS) Dated: April 3, 2014. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2014–07863 Filed 4–8–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Pragmatic Research and Natural Experiments. Date: June 11, 2014. Time: 11:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Michele L. Barnard, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 753, 6707 Democracy Boulevard, Bethesda, MD 20892–2542, (301) 594–8898, barnardm@extra.niddk.nih.gov. E:\FR\FM\09APN1.SGM 09APN1

Agencies

[Federal Register Volume 79, Number 68 (Wednesday, April 9, 2014)]
[Notices]
[Page 19637]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-07863]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; Review of Grant Applications.
    Date: May 2, 2014.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Natcher Building, 45 
Center Drive, Room 3An.18B, Bethesda, MD 20892, (Telephone 
Conference Call).
    Contact Person: Margaret J. Weidman, Ph.D., Scientific Review 
Officer, Office of Scientific Review, National Institute of General 
Medical Sciences, National Institutes of Health, 45 Center Drive, 
Room 3An.18B, Bethesda, MD 20892, 301-594-2773, 
weidmanma@nigms.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives, National Institutes of Health, HHS)

    Dated: April 3, 2014.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-07863 Filed 4-8-14; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.